60 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
for commercial operations in the U.S. designed to support the commercialization of APHEXDA. In addition, we completed the onboarding of customer-facing
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
constraints of the third parties;
impact on our reputation in the marketplace if manufacturers of our products, once commercialized, fail to meet customer … operations in the U.S. designed to support the commercialization of APHEXDA. In addition, we completed the onboarding of customer-facing personnel
F-3
BLRX
Bioline Rx Ltd
29 Dec 23
Shelf registration (foreign)
4:15pm
they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold debt securities in street name
424B5
elz09
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
a2por4p
15 Sep 22
Current report (foreign)
8:39am
424B5
7d7 kxupw5s
3 Sep 21
Prospectus supplement for primary offering
4:29pm
424B5
6gopf3
21 Jan 21
Prospectus supplement for primary offering
4:31pm
424B5
vy1cc
19 Jan 21
Prospectus supplement for primary offering
5:00pm
F-3
bja97ott
31 Dec 20
Shelf registration (foreign)
4:37pm
424B5
5nlq0py65q
25 Sep 20
Prospectus supplement for primary offering
4:30pm
424B5
bhb7gt
3 Jun 20
Prospectus supplement for primary offering
8:33am
424B5
qtu2zu743r8 9thrcd6v
28 May 20
Prospectus supplement for primary offering
12:00pm
6-K
EX-99
k3p5ekz328jt7fh o2s
7 Feb 19
As Representative of the several Underwriters
12:00pm
424B5
e02zwevisjxnzacd8b
5 Feb 19
Prospectus supplement for primary offering
5:12pm